Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022161346 - ANTIBODY AGAINST SARS-COV-2

Publication Number WO/2022/161346
Publication Date 04.08.2022
International Application No. PCT/CN2022/073733
International Filing Date 25.01.2022
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61K 39/42 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/569
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applicants
  • BIODURO (JIANGSU) CO., LTD. [CN]/[CN]
Inventors
  • LI, Xiang
  • XIONG, Yi
  • HOU, Shin-Chen
  • CAI, Chenguang
  • GUAN, Yanbin
Agents
  • LIU, SHEN & ASSOCIATES
Priority Data
PCT/CN2021/07391727.01.2021CN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTIBODY AGAINST SARS-COV-2
(FR) ANTICORPS DIRIGÉ CONTRE LE SARS-COV-2
Abstract
(EN) A nanobody capable of specifically recognizing SARS-CoV-2 spike glycoprotein RBD is provided, and the nanobody comprises a CDR having an amino acid sequence selected from at least one of the following or at least 95%identical to the following: a CDR sequence of a heavy chain variable region: SEQ ID NO: 1~21.
(FR) L'invention concerne un nanocorps capable de reconnaître spécifiquement la glycoprotéine RBD de spicule du SARS-CoV-2, le nanocorps comprenant un CDR ayant une séquence d'acides aminés choisie parmi au moins l'un des éléments suivants ou au moins 95 % identiques aux éléments suivants : une séquence CDR d'une région variable de chaîne lourde : SEQ ID NO : 1 à 21.
Latest bibliographic data on file with the International Bureau